Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating)’s share price traded up 1.4% during mid-day trading on Monday . The stock traded as high as $1.40 and last traded at $1.40. 1,936,226 shares traded hands during mid-day trading, an increase of 48% from the average session volume of 1,306,067 shares. The stock had previously closed at $1.38.
Citius Pharmaceuticals Trading Down 0.8 %
The company has a market capitalization of $172.53 million, a PE ratio of -5.41 and a beta of 1.21. The firm’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.10.
Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) last released its quarterly earnings data on Thursday, December 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, analysts anticipate that Citius Pharmaceuticals, Inc. will post 0.43 EPS for the current year.
Institutional Investors Weigh In On Citius Pharmaceuticals
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite.
- Get a free copy of the StockNews.com research report on Citius Pharmaceuticals (CTXR)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.